McKesson Corporation (BMV:MCK)
Mexico
· Delayed Price · Currency is MXN 13,563
0.00 (0.00%)
At close: May 12, 2025, 2:00 PM CST
Revenue by Product
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Medical Surgical Solutions | 11.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Growth | 1.84% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical | 313.34B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Growth | 15.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions | 5.06B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Growth | 5.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International | 14.81B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Growth | 6.19% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Capex by Product
Fiscal year is April - March.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2019 |
|---|---|---|---|---|---|
Period Ending | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2019 |
| Medical Surgical Solutions Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Capital Expenditures |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Capital Expenditures Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is April - March.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2017 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2017 - 2020 |
| Medical Surgical Solutions Operating Profit | 759.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Surgical Solutions Operating Profit Growth | -21.99% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Operating Profit | 3.77B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| US Pharmaceutical Operating Profit Growth | 51.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Operating Profit | 815.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Prescription Technology Solutions Operating Profit Growth | 0.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Operating Profit | -237.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Operating Profit Growth | -181.16% |
Log In |
Log In |
Log In |
Log In | Upgrade
|